How Pfizer Scaled Up Manufacturing of Their Breakthrough Vaccine to Help Protect Against the Spread of COVID-19

At Pfizer, we worked at an unprecedented speed to execute one of the most successful manufacturing operations and distribution in history to help prevent COVID-19.

Manufacturing Capabilities

Pfizer operates one of the most sophisticated supply chain systems in the industry, with more than 40 owned sites and more than 300 suppliers globally.

Globally, we have more than 28,000 colleagues

Supplying vaccines to 165 countries

Producing more than 25 billion doses of medications per year, including +3.2 billion vaccine doses + 1.6 billion sterile units

For biologics, vaccines & sterile injectables, we have:

17,000 colleagues

in 23 manufacturing facilities

Capacity to manufacture more than 4.8 billion doses of biologics, vaccines & sterile injectables
An Unprecedented Manufacturing Success

In 2021, Pfizer met its commitment to manufacture more than 3 billion doses of the Pfizer-BioNTech COVID-19 Vaccine worldwide and is expected to manufacture 4 billion doses worldwide in 2022.

Pfizer has manufacturing and distribution sites across the U.S. for the COVID-19 vaccine program, we are leveraging five of them:

How It Happened

Pfizer's manufacturing and supply chain professionals took several steps to accelerate the scale-up and manufacturing if the vaccine to ensure it was one of the most successful manufacturing operations in history.

- Exchanging technology to enable rapid facility, equipment and process design planning
- Maintaining two parallel supply chains for appropriate redundancies
- Modifying facilities for the vaccine formulations and re-prioritizing capacity
- Hiring and training staff to give our operations even more support and flexibility
- Investing at risk so we can quickly produce as many doses of vaccine as possible